$101 Million

Cardiff Oncology

Follow-on Offering

Lead Left Bookrunner, September 2020

Cardiff Oncology

Cardiff is a clinical-stage oncology company developing drugs that target mitosis to treat various types of cancer, including colorectal, prostate and leukemia. The Company licensed onvansertib, a first-in-class, third-generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. PLK1, a serine/threonine kinase, is a master regulator of mitotic progression with various roles and localizations during different mitotic phases. Upon PLK1 depletion in cancer cells by RNA interference, inhibition of proliferation and decreased viability, are observed. PLK1 depletion also results in an increase in the number of cells containing abnormal spindle formation and misaligned chromosomes. Expression of PLK1 is seen in all proliferating normal tissues, and PLK1 is overexpressed in a number of tumors (including breast, prostate, ovary, lung, gastric, and colon cancers), as well as in hematologic cancers. The Company currently has three active clinical trials for onvansertib: TROV-O54, TROV-053 and TROV-052.